Desoximetasone (Desoximetasone Topical) - Summary

DESOXIMETASONE SUMMARY

DESOXIMETASONE GEL USP, 0.05%

Desoximetasone Gel USP, 0.05% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Each gram of Desoximetasone Gel USP, 0.05% contains 0.5 mg desoximetasone in a gel consisting of purified water USP, docusate sodium USP, edetate disodium USP, isopropyl myristate NF, carbomer 940, trolamine NF, SD alcohol 40 (20% w/w).

Desoximetasone Gel USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

See all Desoximetasone indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Desoximetasone (Desoximetasone Topical)

Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. [2006.11]
Long-term in vitro compatibility of desoximetasone and tacrolimus ointments prompted the current trial in humans. We aimed to evaluate the efficacy of twice-daily simultaneous application of desoximetasone and tacrolimus in the treatment of atopic dermatitis versus tacrolimus monotherapy.Combination treatment with desoximetasone and tacrolimus offered increased efficacy and tolerability over tacrolimus alone in patients with atopic dermatitis.

Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. [2008]
INTRODUCTION: We report on a double-blind, vehicle-controlled, single-center confirmatory study with random assignment. The purpose of the study was to investigate the topical bioavailability of different topical corticosteroid formulations in healthy human beings focussing on desoximetasone (DM)... CONCLUSION: DM-o 0.25%, DM-fo 0.25% and BM 0.05% showed similar vasoconstrictive potential, i.e., clear blanching. In fact, both DM preparations were proven to be noninferior to BM 0.05%, while CP 0.05% was found a little less active. HC 1.0% and the DM vehicles showed no clear-cut vasoconstrictive effect. No adverse events related to the study medications were observed. Good topical bioavailability of both DM formulations was detected by chromametric measurement and clinical assessment. (c) 2008 S. Karger AG, Basel.

Cross-reactions to desoximetasone and mometasone furoate in a patient with multiple topical corticosteroid allergies. [2006.09]
A 60-year-old man developed a bullous contact dermatitis after topical corticosteroid treatment of dermatitis on his lower leg. Subsequent patch testing showed cross-reactions to numerous group B and group D corticosteroids as well as cross-reactions to group C desoximetasone and group D1 mometasone furoate.

Compatibility of desoximetasone and tacrolimus. [2003.12]
The physical and chemical compatibility of desoximetasone ointment 0.25% and tacrolimus ointment 0.1%, both widely used to treat atopic dermatitis, were determined. A 1:1 (w/w) mixture of desoximetasone ointment 0.25% (Topicort, Taro Pharmaceuticals USA, Inc.) and tacrolimus ointment 0.1% (Protopic, Fujisawa Healthcare, Inc.) were prepared and stored under three different temperature/relative humidity conditions: 25 degrees C/60% RH; 30 degrees C/60% RH; and 40 degrees C/75% RH...

more studies >>

Clinical Trials Related to Desoximetasone (Desoximetasone Topical)

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis [Recruiting]
The objective of this study is to demonstrate that desoximetasone 0. 25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis [Recruiting]
The objective of this study is to demonstrate that desoximetasone 0. 25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study [Recruiting]
The objective of this study is to evaluate the potential of desoximetasone 0. 25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0. 25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile.

more trials >>

Reports of Suspected Desoximetasone (Desoximetasone Topical) Side Effects

Drug Ineffective (8),  Pruritus (7),  Blister (6),  Depression (4),  Hyperhidrosis (3),  Mood Altered (3),  Drug Administration Error (3),  Irritability (3),  Condition Aggravated (2),  DRY Skin (2), more >>